Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30986688 | 0.98 | NPC1 (0.48) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| Bicarbonate SCHEMBL30250535 | 0.90 | GAA (0.45) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL15964648 | 0.89 | MAPT (0.53) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL15479700 | 0.80 | SMN1; SMN2 (0.48) | BRD4CREBBPALOX5ITGB2ICAM1 | |
| SCHEMBL88746 | 0.80 | MMP12 (0.58) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL30293243 | 0.78 | MMP12 (0.56) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL6518631 | 0.78 | MMP12 (0.56) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11442210 | 0.77 | ALOX5 (0.48) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL24720317 | 0.75 | CMA1 (0.45) | BRD4MAPTAHRLMNAHTT | |
| SCHEMBL3485856 | 0.75 | FABP6 (0.43) | MAPTNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | claimed |
| EP-1021190-B1 | Amid derivatives as growth hormone release promotors | KAKEN PHARMA CO LTD (JP) | 2006-11-08 | — | — | EP | claimed |
| EP-1021190-A4 | NOVEL AMIDE DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2004-08-18 | — | — | EP | claimed |
| EP-1021190-A1 | NOVEL AMIDE DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2000-07-26 | — | — | EP | claimed |
| WO-1999009991-A1 | NOVEL AMIDE DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1999-03-04 | — | — | WO | claimed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2024163956-A2 | SIGMA RECEPTOR LIGAND COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024140401-A1 | HETEROCYCLIC COMPOUND ACTING AS KINASE INHIBITOR, AND COMPOSITION COMPRISING SAME | 捷思英达控股有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| WO-2023020486-A1 | RIP1 KINASE INHIBITOR COMPOUND AND COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2023-02-23 | — | — | WO | disclosed |
| WO-2004080969-A1 | QUINOLINONE / BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | ROCHE PALO ALTO LLC | 2004-09-23 | — | — | US | disclosed |
| WO-2004041792-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC | 2004-05-13 | — | — | US | disclosed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | disclosed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0154969-A2 | Piperazine derivatives and their acid addition salts | MITSUBISHI KASEI CORPORATION (JP) | 1985-09-18 | — | — | EP | disclosed |
| US-4477464-A | Hetero-benzazepine derivatives and their pharmaceutical use | CIBA-GEIGY CORPORATION (US) | 1984-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | NQO2, UGT1A8, UGT1A1 | NPC1 1939/4885MAPK13 4535/4885MAPK12 4562/4885 |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARG, PPARD | NPC1 785/4885MAPK13 2045/4885MAPK12 1233/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | NPC1 541/4885MAPK13 4732/4885MAPK12 4665/4885 |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | BACH1, BACE1, CMA1 | NPC1 936/4885MAPK13 1382/4885MAPK12 2847/4885 |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | CYP4X1, CYP3A5, CYP2D6 | NPC1 1463/4885MAPK13 4549/4885MAPK12 3639/4885 |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | NPC1 976/4885MAPK13 656/4885MAPK12 897/4885 |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | NPC1 785/4885MAPK13 2045/4885MAPK12 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.